<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">EJNMMI Res</journal-id><journal-id journal-id-type="iso-abbrev">EJNMMI Res</journal-id><journal-title-group><journal-title>EJNMMI Research</journal-title></journal-title-group><issn pub-type="epub">2191-219X</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24308868</article-id><article-id pub-id-type="pmc">4029781</article-id><article-id pub-id-type="publisher-id">2191-219X-3-79</article-id><article-id pub-id-type="doi">10.1186/2191-219X-3-79</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Intervention versus standard medical treatment in patients with symptomatic occlusion of the internal carotid artery: a randomised oxygen-15 PET study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Persoon</surname><given-names>Suzanne</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s.persoon@umcutrecht.nl</email></contrib><contrib contrib-type="author" id="A2"><name><surname>van Berckel</surname><given-names>Bart NM</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>b.berckel@vumc.nl</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Bremmer</surname><given-names>Jochem P</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jochem.bremmer@gmail.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Boellaard</surname><given-names>Ronald</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>r.boellaard@vumc.nl</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Algra</surname><given-names>Ale</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>a.algra@umcutrecht.nl</email></contrib><contrib contrib-type="author" id="A6"><name><surname>de Borst</surname><given-names>Gert Jan</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>g.j.deborst-2@umcutrecht.nl</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Lammertsma</surname><given-names>Adriaan A</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>aa.lammertsma@vumc.nl</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Kappelle</surname><given-names>L Jaap</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>l.kappelle@umcutrecht.nl</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Klijn</surname><given-names>Catharina JM</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>c.j.m.klijn@umcutrecht.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Neurology and Neurosurgery, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, G03.228, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands</aff><aff id="I2"><label>2</label>Department of Nuclear Medicine &#x00026; PET research, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands</aff><aff id="I3"><label>3</label>Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands</aff><aff id="I4"><label>4</label>Department of Vascular Surgery, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2013</year></pub-date><volume>3</volume><fpage>79</fpage><lpage>79</lpage><history><date date-type="received"><day>22</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>25</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Persoon et al.; licensee Springer.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Persoon et al.; licensee Springer.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.ejnmmires.com/content/3/1/79"/><abstract><sec><title>Background</title><p>The aim of this randomised pilot study was to investigate the haemodynamic effects measured by oxygen-15 positron emission tomography (PET) of interventional treatment consisting of either endarterectomy or endovascular treatment of stenosed cerebropetal arteries, or tapering of antihypertensive medication in comparison with standard medical treatment alone in patients with symptomatic internal carotid artery (ICA) occlusion.</p></sec><sec><title>Methods</title><p>Twenty-three patients with symptomatic ICA occlusion underwent PET scanning at baseline and after 3&#x000a0;months. Twelve patients were randomised to intervention (either endarterectomy or endovascular treatment of stenosed cerebropetal arteries, or tapering of antihypertensive medication) and 11 to standard medical treatment alone. Primary outcome was a change in cerebral blood flow (CBF), cerebral blood volume (CBV) and/or oxygen extraction fraction (OEF) after 3&#x000a0;months measured by PET.</p></sec><sec><title>Results</title><p>There were no differences in changes in CBF, CBV or OEF between the two groups. Only patients with compromised perfusion at presentation showed a borderline significant increase in CBF of 2.8&#x000a0;mL/min/100&#x000a0;mL (95% confidence interval 0.0 to 5.7) after intervention (<italic>n</italic>&#x02009;=&#x02009;7).</p></sec><sec><title>Conclusion</title><p>This pilot study shows that in patients with symptomatic ICA occlusion, oxygen-15 PET did not detect differences in improvement of CBF, CBV or OEF between interventional and standard treatment.</p></sec></abstract><kwd-group><kwd>Carotid artery diseases</kwd><kwd>Haemodynamics</kwd><kwd>Other cerebrovascular disease/stroke</kwd><kwd>PET</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>In patients with transient ischaemic attack (TIA) or minor disabling ischaemic stroke associated with an occlusion of the internal carotid artery (ICA), the risk of recurrent stroke has been reported 5% to 6% per year [<xref ref-type="bibr" rid="B1">1</xref>]. This risk may be as high as 12% per year in case of a demonstrated compromised flow to the brain [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. In these &#x02018;high-risk&#x02019; patients, revascularization surgery may be considered, but evidence that interventional treatment reduce the risk of stroke in comparison with the standard treatment consisting of antithrombotic medication and control of vascular risk factors is lacking.</p><p>A recent study has shown that increased oxygen extraction fraction (OEF) measured by positron emission tomography (PET) is still an independent predictor of subsequent stroke under current medical treatment [<xref ref-type="bibr" rid="B5">5</xref>]. However, the Carotid Occlusion Surgery Study (COSS) included patients with symptomatic ICA occlusion and poor cerebral haemodynamics as demonstrated by increased OEF measured by PET and found no benefit of extracranial/intracranial (EC/IC) bypass surgery [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. This trial was stopped prematurely as the 2-year risk of ipsilateral stroke was between 20% and 25% in both surgical and non-surgical groups (<italic>p</italic>&#x02009;=&#x02009;.78). In this study, the proportion of patients who had a perioperative stroke (within 30&#x000a0;days after surgery) was 15% [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Other therapeutic strategies in patients with symptomatic ICA occlusion aiming to improve cerebral perfusion and reducing the risk of recurrent stroke are endarterectomy or endovascular treatment of a significant stenosis in one of the cerebropetal arteries that are part of collateral pathways [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B10">10</xref>], or tapering of antihypertensive medication [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>].</p><p>These procedures have lower perioperative risks than an EC/IC bypass operation, but so far, their clinical effect has not been compared to standard treatment. Whether the application of these therapeutic strategies improves cerebral perfusion as compared with standard medical treatment is unclear.</p><p>The aim of this randomised pilot study was to investigate the haemodynamic effects as measured by oxygen-15 PET of endarterectomy or endovascular treatment of stenosed cerebropetal arteries, or tapering of antihypertensive medication in comparison with the standard medical treatment alone in patients with a symptomatic ICA occlusion.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>Between December 2004 and September 2009, patients who had been referred to the University Medical Center Utrecht with a symptomatic ICA occlusion were considered for participation. Inclusion criteria were (1) transient or at most, moderately disabling (modified Rankin scale&#x02009;&#x02264;&#x02009;3 [<xref ref-type="bibr" rid="B13">13</xref>]) neurological deficits associated with ischaemia in the hemisphere ipsilateral to the ICA occlusion, (2) ICA occlusion proven by angiograph and (3) symptoms present within the previous 3&#x000a0;months. Exclusion criteria were (1) ICA occlusion caused by arterial dissection or radiation vasculopathy, (2) contra-indications for magnetic resonance imaging (MRI) (claustrophobia or metal objects in the body) or PET (pregnancy, blood donation in the previous 3&#x000a0;months or haemoglobin concentration &#x0003c;8.0&#x000a0;mmol/L) and (3) absence of any of the conditions that could be treated according to the therapeutic strategy (see below). All patients were interviewed regarding symptoms and risk factors as listed in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>, underwent neurological examination, measurement of blood pressure and blood tests for glucose and lipids. Contrast angiography was performed to confirm occlusion of the ICA by absence of filling of the extracranial ICA, to assess collateral blood supply to the symptomatic hemisphere, and the presence of stenosis in the cerebropetal arteries [<xref ref-type="bibr" rid="B14">14</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p><bold>Clinical characteristics and angiographic findings of patients with symptomatic occlusion of the internal carotid artery (</bold><bold><italic>n</italic></bold>&#x02009;<bold>=&#x02009;23)</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="left"><bold>Intervention </bold><bold><italic>n</italic></bold>&#x02009;<bold>=&#x02009;12</bold></th><th align="left"><bold>Standard </bold><bold><italic>n</italic></bold>&#x02009;<bold>=&#x02009;11</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Age (years, mean&#x02009;&#x000b1;&#x02009;SD)<hr/></td><td align="left" valign="bottom">68&#x02009;&#x000b1;&#x02009;10<hr/></td><td align="left" valign="bottom">60&#x02009;&#x000b1;&#x02009;12<hr/></td></tr><tr><td align="left" valign="bottom">Male<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">7<hr/></td></tr><tr><td align="left" valign="bottom">Clinical features at presentation<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Cerebral TIA<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">8<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Ischaemic stroke<hr/></td><td align="left" valign="bottom">3<hr/></td><td align="left" valign="bottom">3<hr/></td></tr><tr><td align="left" valign="bottom">Systolic blood pressure (mmHg, mean&#x02009;&#x000b1;&#x02009;SD )<hr/></td><td align="left" valign="bottom">159&#x02009;&#x000b1;&#x02009;25<hr/></td><td align="left" valign="bottom">167&#x02009;&#x000b1;&#x02009;29<hr/></td></tr><tr><td align="left" valign="bottom">Diastolic blood pressure (mmHg, mean&#x02009;&#x000b1;&#x02009;SD)<hr/></td><td align="left" valign="bottom">84&#x02009;&#x000b1;&#x02009;15<hr/></td><td align="left" valign="bottom">91&#x02009;&#x000b1;&#x02009;13<hr/></td></tr><tr><td align="left" valign="bottom">Vascular risk factors<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Hypertension<sup>a</sup><hr/></td><td align="left" valign="bottom">10<hr/></td><td align="left" valign="bottom">10<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Hyperlipidaemia<sup>b</sup><hr/></td><td align="left" valign="bottom">10<hr/></td><td align="left" valign="bottom">10<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Diabetes mellitus<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">3<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Cigarette smoking (current or in last 5&#x000a0;years)<hr/></td><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">7<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;History of stroke &#x0003e;3&#x000a0;months ago<hr/></td><td align="left" valign="bottom">3<hr/></td><td align="left" valign="bottom">4<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;History of ischaemic heart disease<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6<hr/></td></tr><tr><td align="left" valign="bottom">Angiogram<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Contralateral ICA stenosis 50% to 69%<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">2<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Stenosis 70% to 99%<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">2<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Occlusion<hr/></td><td align="left" valign="bottom">0<hr/></td><td align="left" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">Ipsilateral ECA stenosis&#x02009;&#x02265;&#x02009;50%<hr/></td><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">Vertebral artery stenosis&#x02009;&#x02265;&#x02009;50%<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">5<hr/></td></tr><tr><td align="left" valign="bottom">Collateral flow via anterior communicating artery<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">10<hr/></td></tr><tr><td align="left" valign="bottom">Collateral flow via ophthalmic artery<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">5<hr/></td></tr><tr><td align="left" valign="bottom">Collateral flow via posterior communicating artery<hr/></td><td align="left" valign="bottom">9<sup>c</sup><hr/></td><td align="left" valign="bottom">11<hr/></td></tr><tr><td align="left">Leptomeningeal collaterals</td><td align="left">7<sup>d</sup></td><td align="left">9</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Blood pressure&#x02009;&#x0003e;&#x02009;160/95&#x000a0;mmHg or the current use of antihypertensive medication; <sup>b</sup>patients with either a history of hyperlipidaemia, patients on statins or patients with levels of total cholesterol, triglycerids or high density lipoprotein cholesterol outside normal ranges; <sup>c</sup>the presence of collateral flow via the posterior communicating artery could not be judged in one patient; <sup>d</sup>the presence of leptomeningeal collaterals could not be judged in two patients.</p></table-wrap-foot></table-wrap><p>Patients were randomised between any intervention according to therapeutic strategy or standard medical treatment. In the intervention group, the therapeutic strategy consisted of, in order of preference, one of the following treatment options: (1) endarterectomy (CEA) of the contralateral ICA in case of a severe contralateral ICA stenosis in the presence of a functional anterior circle of Willis, (2) CEA of the external carotid artery (ECA) in case of a severe ipsilateral ECA stenosis in the presence of collateral blood supply via the ECA and ophthalmic artery, (3) endovascular treatment of the vertebral artery (VA) or subclavian artery in case of a severely stenosed VA or subclavian artery in the presence of collaterals via the vertebrobasilar system and (4) tapering of antihypertensive medication for 3&#x000a0;months. In addition to the intervention, patients received standard medical treatment consisting of antithrombotic medication (aspirin and dipyridamole), a statin, treatment of hypertension to a targeted blood pressure of 140/90&#x000a0;mmHg (except for those randomised to tapering of antihypertensive drugs) and control of other vascular risk factors such as smoking and obesity. To ensure equal distribution of patients with a low CBF in both groups [<xref ref-type="bibr" rid="B15">15</xref>], randomisation was carried out by minimisation for CBF in three categories (CBF&#x02009;&#x02264;&#x02009;33&#x000a0;mL/100&#x000a0;g/min, CBF between 34 and 53&#x000a0;mL/100&#x000a0;g/min or CBF&#x02009;&#x02265;&#x02009;54&#x000a0;mL/100&#x000a0;g/min), measured in the MCA territory of the symptomatic hemisphere by arterial spin labelling (ASL)-MRI [<xref ref-type="bibr" rid="B16">16</xref>]. The ASL-MRI scan was made within 1 to 15&#x000a0;days of the baseline PET study, and included a three-dimensional (3D) T1 image for PET image analysis. Patients were examined by oxygen-15 PET at the time of inclusion and 3&#x000a0;months thereafter. Primary outcome was a change in CBF, CBV and/or OEF as measured by PET after 3&#x000a0;months. During those 3&#x000a0;months, we documented whether patients had recurrent TIA or stroke, defined as an acute onset of transient (&#x0003c;24&#x000a0;h) or permanent new focal neurological deficits of cerebral origin without haemorrhage on CT or MRI.</p><p>The institutional medical review board approved the study protocol, and all patients provided written informed consent.</p></sec><sec><title>PET data acquisition</title><p>Oxygen-15 PET scans were acquired using an ECAT EXACT HR&#x02009;+&#x02009;scanner (CTI/Siemens, Knoxville, TN, USA) [<xref ref-type="bibr" rid="B17">17</xref>]. Each PET study consisted of three parts: (1) a dynamic emission scan (25 frames over 600&#x000a0;s) after intravenous administration of a bolus of 1,100&#x000a0;MBq [<sup>15</sup>O]H<sub>2</sub>O to measure CBF; (2) a dynamic emission scan (20 frames over 600&#x000a0;s) after a 30-s net inhalation of approximately 300&#x000a0;MBq [<sup>15</sup>O]O<sub>2</sub> gas through a nasal cannula to derive oxygen consumption and calculate OEF; (3) an emission scan (3 frames over 360&#x000a0;s) following a net inhalation of approximately 200&#x000a0;MBq [<sup>15</sup>O]CO gas to measure CBV. Further details of the scanning procedure can be found elsewhere [<xref ref-type="bibr" rid="B18">18</xref>].</p></sec><sec><title>Image analysis</title><p>Individual anatomical 3D T1 MR images were co-registered with summed [<sup>15</sup>O]H<sub>2</sub>O images. A standard template of flow territories of middle cerebral artery (MCA), anterior cerebral artery (ACA) and posterior cerebral artery (PCA) [<xref ref-type="bibr" rid="B19">19</xref>] was warped onto the co-registered MR image using Automated Image Registration (AIR) software [<xref ref-type="bibr" rid="B20">20</xref>], applying non-rigid 12 parameter perspective warping. Statistical Parametric Mapping (SPM02, London, UK, application in Matlab 7.0.4; MathWorks, Inc., Natick, MD, USA) was used for segmentation of grey and white matter. Areas of infarction were excluded manually. Parametric CBF, CBV and OEF images were generated using in-house developed software (written in IDL, 6.2, ITT, Boulder CO, USA) [<xref ref-type="bibr" rid="B21">21</xref>].</p></sec><sec><title>Data analysis</title><p>Normal CBF, CBV and OEF values were derived from 14 scans in seven healthy subjects (mean age 66&#x02009;&#x000b1;&#x02009;7&#x000a0;years; five men). They were all in a good physical and mental condition, which had been evaluated with medical history, a physical examination and screening laboratory tests. Subjects with a history of psychiatric or neurological illness, a Mini Mental State Examination score&#x02009;&#x02264;&#x02009;27 or any significant abnormality of a laboratory test were excluded. They underwent a PET scan on two separate occasions with a median time interval of 7&#x000a0;days, as published previously [<xref ref-type="bibr" rid="B18">18</xref>]. CBF, CBV and OEF values in patients were considered to be abnormal if they were beyond mean values of normal controls &#x000b1;1.96 times the standard deviation (SD). Patients were divided into haemodynamic stages based on their values in grey matter of the affected MCA territory: patients with normal CBF (&#x02265;31.1&#x000a0;mL/min/100&#x000a0;mL), normal CBV (&#x02264;3.9&#x000a0;mL/100&#x000a0;mL) and normal OEF (&#x02264;55.7%) were classified in haemodynamic stage 0, patients with either decreased CBF (&#x0003c;31.1&#x000a0;mL/min/100&#x000a0;mL) or increased CBV (&#x0003e;3.9&#x000a0;mL/100&#x000a0;mL), but normal OEF in haemodynamic stage 1, and patients with increased OEF (&#x0003e;55.7%) in haemodynamic stage 2.</p><p>We compared mean CBF in the MCA territory of patients with data in healthy subjects [<xref ref-type="bibr" rid="B18">18</xref>] and calculated a mean difference with 95% confidence interval (CI). In the patients, differences between mean baseline grey matter CBF, CBV and OEF values in ACA and MCA territories of patients at baseline and after 3&#x000a0;months were assessed by paired <italic>t</italic> tests with 95% confidence interval (CI). Mean absolute change, adjusted for age and sex, in CBF, CBV and OEF was compared between patients assigned to intervention and those who received standard treatment using linear regression analysis, and results were expressed as adjusted mean differences in change with 95% CI. Finally, pre-specified subgroup analyses were performed in patients with haemodynamic stage 1 or 2 at presentation and between patients who were randomised to treatment with surgery or stenting of a stenosis in a collateral artery (excluding those who had tapering of antihypertensive medication) and those who received standard medical treatment.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Complete PET data sets were obtained for 23 patients (mean age 64&#x02009;&#x000b1;&#x02009;11&#x000a0;years; 19 men). Of 41 eligible patients, 14 failed to complete the initial PET study and were excluded and four others did not complete the PET study after 3&#x000a0;months (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). Twelve patients were assigned to intervention (eight stenting or surgery and four tapering of antihypertensive medication) and 11 to standard treatment. Clinical characteristics and presence of stenosis in cerebropetal arteries and collateral pathways are shown in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>. Twenty-two patients had had recurrent ischaemic symptoms after the ICA occlusion had been demonstrated, but before inclusion in the study. The time between last symptoms and first PET scan was on average 38&#x02009;&#x000b1;&#x02009;23&#x000a0;days in both treatment groups. At baseline, ten patients were characterized as haemodynamic stage 0, 11 as stage 1 and two as stage 2. Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref> shows parametric images of a typical patient with stage 2 haemodynamic failure. Patients with a symptomatic ICA occlusion had a mean CBF in the ipsilateral MCA territory of 32.2&#x02009;&#x000b1;&#x02009;5.6, which was significantly lower (mean difference &#x02212;5.2&#x000a0;mL/min/100&#x000a0;mL, 95% CI &#x02212;9.8 to &#x02212;0.6) than that in healthy subjects (mean CBF MCA territory of 37.4&#x02009;&#x000b1;&#x02009;3.2) [<xref ref-type="bibr" rid="B18">18</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Trial profile.</bold> CEA, carotid endarterectomy; ICA, internal carotid artery; ECA, external carotid artery; VA, vertebral artery; SA, subclavian artery.</p></caption><graphic xlink:href="2191-219X-3-79-1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Parametric images of a patient with stage 2 haemodynamic failure.</bold> This 69-year-old man presented with a minor ischaemic stroke (without infarction on his MRI) and recurrent TIAs from the left hemisphere associated with a left ICA occlusion. The baseline PET study showed decreased cerebral blood flow (CBF) and increased oxygen extraction fraction (OEF) in the territories of both anterior and middle cerebral artery of the left hemisphere. This patient was randomised for tapering of antihypertensive medication. The PET study after 3&#x000a0;months showed a slight improvement in CBF and OEF. However, he still had recurrent TIAs in the presence of stage 2 haemodynamic failure.</p></caption><graphic xlink:href="2191-219X-3-79-2"/></fig><p>The mean time between PET scans at baseline and follow-up was 98&#x02009;&#x000b1;&#x02009;10 (range 77 to 119) days. All patients were treated according to their randomisation. Randomisation occurred on average 5&#x02009;&#x000b1;&#x02009;9&#x000a0;days after the baseline PET scan. Of the 12 patients assigned to intervention (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>), eight patients underwent stenting or surgery after a mean time of 15&#x02009;&#x000b1;&#x02009;10 (range 1 to 29) days following the baseline PET scan. In four patients, antihypertensive medication was tapered, which resulted in a mean increase in systolic blood pressure of 38&#x02009;&#x000b1;&#x02009;9&#x000a0;mmHg. Intervention was complicated by a non-fatal myocardial infarction in one patient who underwent CEA of a contralateral ICA stenosis; none of the procedures were complicated by a stroke or hyperperfusion syndrome.</p><p>Mean values of CBF, CBV and OEF were similar at baseline and after 3&#x000a0;months, both in patients treated with intervention and in those assigned to standard treatment (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>), but CBF changes varied in individual patients (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>). No differences in absolute CBF, CBV and OEF changes after 3&#x000a0;months were observed between patients assigned to intervention and those assigned to standard treatment (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p><bold>Comparison of haemodynamic state of the brain at baseline and after 3&#x000a0;months between patients assigned to intervention and those to standard treatment (</bold><bold><italic>n</italic></bold>&#x02009;<bold>=&#x02009;23)</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th colspan="2" align="left" valign="bottom">&#x000a0;<hr/></th><th align="left" valign="bottom"><bold>Intervention </bold><bold><italic>n</italic></bold>&#x02009;<bold>=&#x02009;12</bold><hr/></th><th align="left" valign="bottom"><bold>Standard </bold><bold><italic>n</italic></bold>&#x02009;<bold>=&#x02009;11</bold><hr/></th><th align="left" valign="bottom"><bold>Unadjusted difference in change (95% CI)</bold><hr/></th><th align="left" valign="bottom"><bold>Adjusted difference in change</bold><sup>
<bold>* </bold>
</sup><bold>(95% CI)</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th><th align="left"><bold>Mean&#x02009;&#x000b1;&#x02009;SD</bold></th><th align="left"><bold>Mean&#x02009;&#x000b1;&#x02009;SD</bold></th><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td rowspan="3" align="left" valign="bottom">CBF MCA (mL/min/100&#x000a0;mL)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">31.3&#x02009;&#x000b1;&#x02009;5.9<hr/></td><td align="left" valign="bottom">33.1&#x02009;&#x000b1;&#x02009;5.4<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">31.6&#x02009;&#x000b1;&#x02009;4.9<hr/></td><td align="left" valign="bottom">33.5&#x02009;&#x000b1;&#x02009;4.7<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Change<hr/></td><td align="left" valign="bottom">0.34&#x02009;&#x000b1;&#x02009;6.2<hr/></td><td align="left" valign="bottom">0.42&#x02009;&#x000b1;&#x02009;4.1<hr/></td><td align="left" valign="bottom">&#x02212;0.1 (&#x02212;4.7 to 4.5)<hr/></td><td align="left" valign="bottom">&#x02212;1.0 (&#x02212;7.4 to 5.4)<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">CBF ACA (mL/min/100&#x000a0;mL)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">32.6&#x02009;&#x000b1;&#x02009;5.8<hr/></td><td align="left" valign="bottom">35.2&#x02009;&#x000b1;&#x02009;5.5<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">32.0&#x02009;&#x000b1;&#x02009;4.2<hr/></td><td align="left" valign="bottom">35.0&#x02009;&#x000b1;&#x02009;5.7<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Change<hr/></td><td align="left" valign="bottom">&#x02212;0.56&#x02009;&#x000b1;&#x02009;6.2<hr/></td><td align="left" valign="bottom">&#x02212;0.28&#x02009;&#x000b1;&#x02009;4.9<hr/></td><td align="left" valign="bottom">&#x02212;0.3 (&#x02212;5.2 to 4.6)<hr/></td><td align="left" valign="bottom">&#x02212;1.6 (&#x02212;8.4 to 5.2)<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">CBV MCA (mL/100&#x000a0;mL)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">3.0&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="left" valign="bottom">3.3&#x02009;&#x000b1;&#x02009;0.9<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">3.5&#x02009;&#x000b1;&#x02009;1.4<hr/></td><td align="left" valign="bottom">3.2&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Change<hr/></td><td align="left" valign="bottom">0.60&#x02009;&#x000b1;&#x02009;1.7<hr/></td><td align="left" valign="bottom">&#x02212;0.09&#x02009;&#x000b1;&#x02009;1.2<hr/></td><td align="left" valign="bottom">0.7 (&#x02212;0.6 to 2.0)<hr/></td><td align="left" valign="bottom">0.09 (&#x02212;1.7 to 1.9)<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">CBV ACA (mL/100&#x000a0;mL)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">3.0&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="left" valign="bottom">3.4&#x02009;&#x000b1;&#x02009;1.0<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">3.5&#x02009;&#x000b1;&#x02009;1.3<hr/></td><td align="left" valign="bottom">3.1&#x02009;&#x000b1;&#x02009;0.7<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Change<hr/></td><td align="left" valign="bottom">0.49&#x02009;&#x000b1;&#x02009;1.6<hr/></td><td align="left" valign="bottom">&#x02212;0.23&#x02009;&#x000b1;&#x02009;1.3<hr/></td><td align="left" valign="bottom">0.7 (&#x02212;0.6 to 2.0)<hr/></td><td align="left" valign="bottom">0.08 (&#x02212;1.6 to 1.8)<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">OEF MCA (%)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">46.4&#x02009;&#x000b1;&#x02009;9.7<hr/></td><td align="left" valign="bottom">47.5&#x02009;&#x000b1;&#x02009;5.5<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">46.3&#x02009;&#x000b1;&#x02009;7.9<hr/></td><td align="left" valign="bottom">48.4&#x02009;&#x000b1;&#x02009;5.8<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Change<hr/></td><td align="left" valign="bottom">&#x02212;0.08&#x02009;&#x000b1;&#x02009;6.1<hr/></td><td align="left" valign="bottom">0.85&#x02009;&#x000b1;&#x02009;6.8<hr/></td><td align="left" valign="bottom">&#x02212;0.9 (&#x02212;6.5 to 4.7)<hr/></td><td align="left" valign="bottom">3.1 (&#x02212;4.1 to 10.3)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">OEF ACA (%)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">44.4&#x02009;&#x000b1;&#x02009;11.2<hr/></td><td align="left" valign="bottom">46.1&#x02009;&#x000b1;&#x02009;6.2<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">44.2&#x02009;&#x000b1;&#x02009;7.3<hr/></td><td align="left" valign="bottom">47.2&#x02009;&#x000b1;&#x02009;5.2<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="left">Change</td><td align="left">&#x02212;0.17&#x02009;&#x000b1;&#x02009;7.4</td><td align="left">1.1&#x02009;&#x000b1;&#x02009;6.3</td><td align="left">&#x02212;1.3 (&#x02212;7.3 to 4.7)</td><td align="left">3.1 (&#x02212;4.6 to 10.8)</td></tr></tbody></table><table-wrap-foot><p>Asterisk &#x02018;*&#x02019; indicates adjusted for age and sex; measurements were performed ipsilateral to the side of the ICA occlusion; CBF, cerebral blood flow; CBV, cerebral blood volume; OEF, oxygen extraction fraction; MCA, middle cerebral artery; ACA, anterior cerebral artery.</p></table-wrap-foot></table-wrap><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>CBF changes over time in the MCA territory for individual patients.</bold> Patients randomised to <bold>(A)</bold> CEA of a contralateral ICA stenosis, <bold>(B)</bold> CEA of an ipsilateral ECA stenosis, <bold>(C)</bold> angioplasty and stent placement of a VA stenosis and <bold>(D)</bold> tapering of antihypertensive medication. Patients randomised to intervention are indicated by continuous lines and patients randomised to standard treatment by dashed lines.</p></caption><graphic xlink:href="2191-219X-3-79-3"/></fig><p>Of the ten patients with normal CBF, CBV and OEF at baseline (haemodynamic stage 0), five underwent interventional treatment (CEA of the contralateral ICA in one, CEA of the ipsilateral ECA in one, stenting of the VA in one, and tapering of antihypertensive medication in two patients), which did not result in a further increase in CBF in the MCA territory (mean difference &#x02212;3.1, 95% CI &#x02212;13.1 to 6.9, Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). Of the 13 patients with haemodynamic compromise (haemodynamic stage 1 or 2), five underwent stenting or surgery (CEA of the contralateral ICA in two, CEA of the ipsilateral ECA in one, and stenting of the VA in two patients), in two, the antihypertensive medication was tapered and six received standard treatment. The seven patients assigned to intervention had a mean CBF in the MCA territory of 27.2&#x02009;&#x000b1;&#x02009;3.4&#x000a0;mL/min/100&#x000a0;mL at baseline, which increased to 30.0&#x02009;&#x000b1;&#x02009;3.9&#x000a0;mL/min/100&#x000a0;mL after 3&#x000a0;months (mean difference 2.8&#x000a0;mL/min/100&#x000a0;mL, 95% CI 0.0 to 5.7). The mean increase in CBF in the MCA territory in patients treated by intervention was, however, not significantly different from the increase in CBF in patients who received standard treatment (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). Mean CBV in the MCA territory in patients with haemodynamic compromise treated with an intervention showed a small non-significant increase but did not differ from the change in CBV in patients who received standard treatment (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). Because only two patients had an increased OEF at baseline, the effect of intervention on mean OEF after 3&#x000a0;months could not be formally compared. One of the two patients was assigned to standard treatment and after 3&#x000a0;months OEF was unchanged. In the other patient antihypertensive medication was tapered and OEF decreased from 72% to 66% after 3&#x000a0;months.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p><bold>Mean CBF and CBV for patients with symptomatic ICA occlusion, classified in haemodynamic stage 0 (</bold><bold><italic>n</italic></bold>&#x02009;<bold>=&#x02009;10) and haemodynamic stage 1 or 2 (</bold><bold><italic>n</italic></bold>&#x02009;<bold>=&#x02009;13)</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th colspan="2" align="left" valign="bottom">&#x000a0;<hr/></th><th align="left" valign="bottom"><bold>Intervention</bold><hr/></th><th align="left" valign="bottom"><bold>Standard</bold><hr/></th><th align="left" valign="bottom"><bold>Unadjusted difference in change (95% CI)</bold><hr/></th><th align="left" valign="bottom"><bold>Adjusted difference in change</bold><sup>
<bold>* </bold>
</sup><bold>(95% CI)</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th><th align="left"><bold>Mean&#x02009;&#x000b1;&#x02009;SD</bold></th><th align="left"><bold>Mean&#x02009;&#x000b1;&#x02009;SD</bold></th><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="bottom">Haemodynamic stage 0<hr/></td><td align="left" valign="bottom"><italic>N</italic>&#x02009;=&#x02009;5<hr/></td><td align="left" valign="bottom"><italic>N</italic>&#x02009;=&#x02009;5<hr/></td><td colspan="2" align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">&#x02003;CBF MCA (mL/min/100&#x000a0;mL)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">37.0&#x02009;&#x000b1;&#x02009;3.0<hr/></td><td align="left" valign="bottom">35.0&#x02009;&#x000b1;&#x02009;5.6<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">33.9&#x02009;&#x000b1;&#x02009;5.8<hr/></td><td align="left" valign="bottom">34.4&#x02009;&#x000b1;&#x02009;5.2<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Change<hr/></td><td align="left" valign="bottom">&#x02212;3.1&#x02009;&#x000b1;&#x02009;8.1<hr/></td><td align="left" valign="bottom">&#x02212;0.6&#x02009;&#x000b1;&#x02009;5.3<hr/></td><td align="left" valign="bottom">&#x02212;2.5 (&#x02212;12.5 to 7.4)<hr/></td><td align="left" valign="bottom">&#x02212;1.7 (&#x02212;15.6 to 12.2)<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">&#x02003;CBV MCA (mL/100&#x000a0;mL)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">3.1&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="left" valign="bottom">2.8&#x02009;&#x000b1;&#x02009;0.7<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">3.0&#x02009;&#x000b1;&#x02009;0.7<hr/></td><td align="left" valign="bottom">3.5&#x02009;&#x000b1;&#x02009;0.4<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Change<hr/></td><td align="left" valign="bottom">&#x02212;0.2&#x02009;&#x000b1;&#x02009;1.1<hr/></td><td align="left" valign="bottom">0.6&#x02009;&#x000b1;&#x02009;1.0<hr/></td><td align="left" valign="bottom">&#x02212;0.8 (&#x02212;2.3 to 0.7)<hr/></td><td align="left" valign="bottom">&#x02212;1.1 (&#x02212;3.2 to 1.1)<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">Haemodynamic stage 1 or 2<hr/></td><td align="left" valign="bottom"><italic>N</italic>&#x02009;=&#x02009;7<hr/></td><td align="left" valign="bottom"><italic>N</italic>&#x02009;=&#x02009;6<hr/></td><td colspan="2" align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">&#x02003;CBF MCA (mL/min/100&#x000a0;mL)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">27.2&#x02009;&#x000b1;&#x02009;3.4<hr/></td><td align="left" valign="bottom">31.5&#x02009;&#x000b1;&#x02009;5.2<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">30.0&#x02009;&#x000b1;&#x02009;3.9<hr/></td><td align="left" valign="bottom">32.8&#x02009;&#x000b1;&#x02009;4.6<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Change<hr/></td><td align="left" valign="bottom">2.8&#x02009;&#x000b1;&#x02009;3.1<hr/></td><td align="left" valign="bottom">1.3&#x02009;&#x000b1;&#x02009;3.2<hr/></td><td align="left" valign="bottom">1.6 (&#x02212;2.2 to 5.4)<hr/></td><td align="left" valign="bottom">&#x02212;1.1 (&#x02212;7.8 to 5.7)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">&#x02003;CBV MCA (mL/100&#x000a0;mL)<hr/></td><td align="left" valign="bottom">Baseline<hr/></td><td align="left" valign="bottom">2.9&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="left" valign="bottom">3.7&#x02009;&#x000b1;&#x02009;0.8<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">3&#x000a0;months<hr/></td><td align="left" valign="bottom">4.0&#x02009;&#x000b1;&#x02009;1.7<hr/></td><td align="left" valign="bottom">3.0&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="left">Change</td><td align="left">1.1&#x02009;&#x000b1;&#x02009;1.9</td><td align="left">&#x02212;0.7&#x02009;&#x000b1;&#x02009;1.1</td><td align="left">1.8 (&#x02212;0.2 to 3.8)</td><td align="left">1.4 (&#x02212;2.4 to 5.1)</td></tr></tbody></table><table-wrap-foot><p>Asterisk &#x02018;*&#x02019; indicates adjusted for age and sex; CBF, cerebral blood flow; CBV, cerebral blood volume; MCA, middle cerebral artery.</p></table-wrap-foot></table-wrap><p>The eight patients treated with surgery or stenting of a stenosis in a collateral artery had a mean CBF of 30.8&#x02009;&#x000b1;&#x02009;5.4&#x000a0;mL/min/100&#x000a0;mL at baseline and 31.8&#x02009;&#x000b1;&#x02009;5.2&#x000a0;mL/min/100&#x000a0;mL after 3&#x000a0;months (mean difference 0.97, 95% CI &#x02212;4.6 to 6.6). In the 11 patients who received standard medical treatment alone, mean CBF was 33.1&#x02009;&#x000b1;&#x02009;5.4&#x000a0;mL/min/100&#x000a0;mL at baseline and 33.5&#x02009;&#x000b1;&#x02009;4.7&#x000a0;mL/min/100&#x000a0;mL after 3&#x000a0;months (mean difference 0.42, 95% CI &#x02212;2.4 to 3.2). The change in CBF did not differ between these two groups of patients (adjusted mean difference of change &#x02212;0.02&#x000a0;mL/min/100&#x000a0;mL, 95% CI &#x02212;7.2 to 7.1).</p><sec><title>Clinical outcome</title><p>During the period between PET scans at baseline and after 3&#x000a0;months, 10 (43%) of 23 patients had one or more recurrent TIAs and none had a stroke. At baseline, five of the ten patients were in haemodynamic stage 0, three in haemodynamic stage 1, and two in haemodynamic stage 2. Two of the eight patients (25%) who underwent CEA or stenting, three of the four (75%) who had tapering of antihypertensive medication and 5 of the 11 (45%) who received standard medical treatment had one or more recurrent TIAs during the 3&#x000a0;months follow-up period between PET scans at baseline and after 3&#x000a0;months. Clinical follow-up continued with an overall median duration of 2.9 (range 0.5 to 4.4) years. Three of the 23 patients (13%) had a recurrent ischaemic stroke during follow-up.</p><p>The first patient experienced multiple TIAs and a minor ischaemic stroke (modified Rankin scale 2) in the hemisphere ipsilateral to the ICA occlusion 47&#x000a0;days after CEA of the contralateral ICA. The second patient had been treated with CEA of the ipsilateral ECA. In this patient, CBF was 37.1&#x000a0;mL/min/100&#x000a0;mL at baseline, which deteriorated to 26.6&#x000a0;mL/min/100&#x000a0;mL after 3&#x000a0;months. Because of ongoing TIAs, he also underwent CEA of the contralateral ICA 5&#x000a0;months after the 3-month PET scan. Nine months later, he had a fatal ischaemic stroke in the hemisphere ipsilateral to the ICA occlusion. The third patient was randomised for standard treatment (not tapering antihypertensive medication). In this patient, CBF was 32.3&#x000a0;mL/min/100&#x000a0;mL at baseline, deteriorating to 28.5&#x000a0;mL/min/100&#x000a0;mL after 3&#x000a0;months. He continued to have TIAs during the period between the two PET scans and thereafter and underwent an uncomplicated EC/IC bypass operation 9&#x000a0;months after randomization. Three months thereafter, he had a fatal ischaemic stroke in the hemisphere contralateral to the ICA occlusion.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study shows that patients with recent symptoms of cerebral ischaemia associated with occlusion of the ICA on average have a lower CBF in the hemisphere ipsilateral to the occlusion than healthy subjects. Oxygen-15 PET showed that interventions aimed at improving cerebral perfusion caused a borderline significant increase in CBF in patients who had an impaired haemodynamic state of the brain at presentation, but improvement in CBF was not different between interventional and standard treatment.</p><p>Current knowledge of cerebral haemodynamic and metabolic changes over time in medically treated patients with an ICA occlusion is based on small patient series, and both improvement and deterioration over time have been described. In one study, ten medically treated patients with symptomatic ICA occlusion and increased OEF underwent a second PET scan after 12 to 59&#x000a0;months [<xref ref-type="bibr" rid="B22">22</xref>]. Over time, patients showed on average an increase in CBF hemispheric (ipsilateral/contralateral) ratio and a decrease in OEF hemispheric ratio, but without changes in absolute values of CBF and OEF [<xref ref-type="bibr" rid="B22">22</xref>]. Another study of seven patients with symptomatic ICA occlusion and normal CBF and OEF at baseline found a significant decrease in CBF and increase in OEF after 24 to 64&#x000a0;months, implicating haemodynamic deterioration over time [<xref ref-type="bibr" rid="B23">23</xref>]. Other studies reported a bilateral increase in cerebrovascular reactivity measured by Transcranial Doppler (TCD) after CEA of a contralateral carotid stenosis in the presence of a symptomatic or asymptomatic ICA occlusion [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. In contrast to these studies, we did not find a significant effect of treatment aimed at improving the flow state of the brain when compared to control patients in a randomised design. A possible explanation could be that the cerebral haemodynamic state also improved without intervention. Patients with haemodynamic compromise at baseline who received standard treatment showed a small non-significant increase in CBF. It has been shown before that patients with ICA occlusion and a compromised flow state of the brain may improve spontaneously over time [<xref ref-type="bibr" rid="B25">25</xref>]. In addition, in patients with a normal haemodynamic state of the brain (stage 0) at baseline who underwent an intervention, particularly those treated by tapering of antihypertensive medication, a further increase in CBF may not be expected because of preserved cerebral autoregulation.</p><p>A limitation of our randomised pilot study is that we did not select patients on the basis of demonstrated cerebral haemodynamic compromise. The design of the study was aimed at including patients at high risk of recurrent stroke by selection on clinical criteria: ischaemic symptoms of the brain after documented occlusion, excluding patients with eye symptoms alone and those with symptoms only before the ICA occlusion were documented without ongoing symptoms thereafter [<xref ref-type="bibr" rid="B26">26</xref>]. We had expected that these clinical criteria would have resulted in a much larger proportion of patients with haemodynamic stages 1 and 2. Because the average time between the last symptoms of patients and the baseline PET scan was 38&#x000a0;days, spontaneous improvement of a compromised flow state of the brain may have occurred before the PET scan took place. This may have contributed to the lack of a difference between the PET scan at baseline and after 3&#x000a0;months.</p><p>Another limitation might be heterogeneity in treating patients assigned to intervention. We have chosen for this randomization scheme rather than designing separate studies for each of the treatment options because all treatment options aim to improve cerebral perfusion. However, effects of tapering of antihypertensive medication on the haemodynamic state of the brain may well be different from those of surgery or stenting of stenosed arteries that may be important for collateral blood supply. Subgroup analysis of the present data comparing surgery or stenting of a stenosis in the contralateral ICA, ipsilateral ECA or VA with standard medical treatment alone did not show significant differences in CBF, but the number of patients in each group was small. Likewise, effects of surgery or stenting of the contralateral ICA on cerebral perfusion may be different than those of surgery or stenting of the ipsilateral ECA or VA. Furthermore, it has been described that both endarterectomy and stenting can be complicated by a hyperperfusion syndrome [<xref ref-type="bibr" rid="B27">27</xref>], but in none of the patients, this complication occurred.</p><p>The third limitation is that a relatively high number of patients had to be excluded because they did not have two successfully performed PET studies. Our failure rate was similar to the rate of 22% for quantitative studies in the St Louis Study [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B6">6</xref>], and lower than in another PET study that reported a failure rate of 41% [<xref ref-type="bibr" rid="B28">28</xref>]. Finally, the sample size in our study was probably too small to detect differences between the two treatment strategies except when they were large.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Although the results of this pilot study are not conclusive, some important lessons can be learned. Patients with TIA or ischaemic stroke in the hemisphere ipsilateral to the ICA occlusion are at risk of subsequent cerebral ischaemia. In these patients with symptomatic ICA occlusion, the clinical benefit of CEA or endovascular treatment of an additional stenosis in the cerebropetal arteries or tapering of antihypertensive medication has not been shown by a randomised trial. The recently published results of the Carotid Occlusion Surgery Study randomised trial [<xref ref-type="bibr" rid="B4">4</xref>] that showed no benefit of STA-MCA bypass surgery over medical treatment despite improvement of cerebral haemodynamics in the surgical group reinforce the need for other therapies to improve outcome in patients with ICA occlusion at high risk of recurrent stroke. Oxygen-15 PET is useful to identify a subgroup of patients with haemodynamic compromise, but we could not demonstrate that stenting or surgery of stenosed cerebropetal arteries or tapering of antihypertensive medication improved the haemodynamic state of the brain to a large extent in comparison with standard treatment. Whether revascularization of collaterals or tapering of antihypertensive medication can reduce the risk of recurrent stroke can only be determined in a large randomised trial of patients with a symptomatic ICA occlusion at high risk of stroke.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have nothing to declare.</p></sec><sec><title>Authors&#x02019; contributions</title><p>SP participated in the design of the study, performed the statistical analysis and drafted the manuscript. JPB, BNMB, RB and AAL were involved in the acquisition and interpretation of the PET studies, and critically revised the manuscript. AA performed the statistical analysis and critically revised the manuscript. GJB, LJK and CJMK participated in the design of the study and critically revised the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>S. Persoon was supported by a grant from the Netherlands Heart Foundation (grant number 2003B263) and the Foundation &#x02018;De Drie Lichten&#x02019; (grant number 41/09). C.J.M. Klijn was supported by the Netherlands Organisation for Health Research and Development (grant number 907-00-103).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Klijn</surname><given-names>CJ</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Algra</surname><given-names>A</given-names></name><name><surname>van Gijn</surname><given-names>J</given-names></name><article-title>Outcome in patients with symptomatic occlusion of the internal carotid artery or intracranial arterial lesions: a meta-analysis of the role of baseline characteristics and type of antithrombotic treatment</article-title><source>Cerebrovasc Dis</source><year>2001</year><volume>3</volume><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1159/000047708</pub-id><pub-id pub-id-type="pmid">11641588</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Klijn</surname><given-names>CJ</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><article-title>Haemodynamic stroke: clinical features, prognosis, and management</article-title><source>Lancet Neurol</source><year>2010</year><volume>3</volume><fpage>1008</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70185-X</pub-id><pub-id pub-id-type="pmid">20864053</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Grubb</surname><given-names>RL</given-names><suffix>Jr</suffix></name><name><surname>Derdeyn</surname><given-names>CP</given-names></name><name><surname>Fritsch</surname><given-names>SM</given-names></name><name><surname>Carpenter</surname><given-names>DA</given-names></name><name><surname>Yundt</surname><given-names>KD</given-names></name><name><surname>Videen</surname><given-names>TO</given-names></name><name><surname>Spitznagel</surname><given-names>EL</given-names></name><name><surname>Powers</surname><given-names>WJ</given-names></name><article-title>Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion</article-title><source>JAMA</source><year>1998</year><volume>3</volume><fpage>1055</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1001/jama.280.12.1055</pub-id><pub-id pub-id-type="pmid">9757852</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Powers</surname><given-names>WJ</given-names></name><name><surname>Clarke</surname><given-names>WR</given-names></name><name><surname>Grubb</surname><given-names>RL</given-names><suffix>Jr</suffix></name><name><surname>Videen</surname><given-names>TO</given-names></name><name><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name><name><surname>Derdeyn</surname><given-names>CP</given-names></name><article-title>Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the carotid occlusion surgery study randomized trial</article-title><source>JAMA</source><year>2011</year><volume>3</volume><fpage>1983</fpage><lpage>1992</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.1610</pub-id><pub-id pub-id-type="pmid">22068990</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Yamauchi</surname><given-names>H</given-names></name><name><surname>Higashi</surname><given-names>T</given-names></name><name><surname>Kagawa</surname><given-names>S</given-names></name><name><surname>Nishii</surname><given-names>R</given-names></name><name><surname>Kudo</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>K</given-names></name><name><surname>Okazawa</surname><given-names>H</given-names></name><name><surname>Fukuyama</surname><given-names>H</given-names></name><article-title>Is misery perfusion still a predictor of stroke in symptomatic major cerebral artery disease?</article-title><source>Brain</source><year>2012</year><volume>3</volume><fpage>2515</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1093/brain/aws131</pub-id><pub-id pub-id-type="pmid">22637544</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Derdeyn</surname><given-names>CP</given-names></name><name><surname>Videen</surname><given-names>TO</given-names></name><name><surname>Yundt</surname><given-names>KD</given-names></name><name><surname>Fritsch</surname><given-names>SM</given-names></name><name><surname>Carpenter</surname><given-names>DA</given-names></name><name><surname>Grubb</surname><given-names>RL</given-names></name><name><surname>Powers</surname><given-names>WJ</given-names></name><article-title>Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited</article-title><source>Brain</source><year>2002</year><volume>3</volume><fpage>595</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1093/brain/awf047</pub-id><pub-id pub-id-type="pmid">11872616</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Gertler</surname><given-names>JP</given-names></name><name><surname>Cambria</surname><given-names>RP</given-names></name><article-title>The role of external carotid endarterectomy in the treatment of ipsilateral internal carotid occlusion: collective review</article-title><source>J Vasc Surg</source><year>1987</year><volume>3</volume><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1067/mva.1987.avs0060158</pub-id><pub-id pub-id-type="pmid">3302317</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Countee</surname><given-names>RW</given-names></name><name><surname>Vijayanathan</surname><given-names>T</given-names></name><article-title>External carotid artery in internal carotid artery occlusion. Angiographic, therapeutic, and prognostic considerations</article-title><source>Stroke</source><year>1979</year><volume>3</volume><fpage>450</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1161/01.STR.10.4.450</pub-id><pub-id pub-id-type="pmid">505484</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Rutgers</surname><given-names>DR</given-names></name><name><surname>Klijn</surname><given-names>CJ</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Eikelboom</surname><given-names>BC</given-names></name><name><surname>van Huffelen</surname><given-names>AC</given-names></name><name><surname>van der Grond</surname><given-names>J</given-names></name><article-title>Sustained bilateral hemodynamic benefit of contralateral carotid endarterectomy in patients with symptomatic internal carotid artery occlusion</article-title><source>Stroke</source><year>2001</year><volume>3</volume><fpage>728</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1161/01.STR.32.3.728</pub-id><pub-id pub-id-type="pmid">11239194</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Baracchini</surname><given-names>C</given-names></name><name><surname>Meneghetti</surname><given-names>G</given-names></name><name><surname>Manara</surname><given-names>R</given-names></name><name><surname>Ermani</surname><given-names>M</given-names></name><name><surname>Ballotta</surname><given-names>E</given-names></name><article-title>Cerebral hemodynamics after contralateral carotid endarterectomy in patients with symptomatic and asymptomatic carotid occlusion: a 10-year follow-up</article-title><source>J Cereb Blood Flow Metab</source><year>2006</year><volume>3</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600260</pub-id><pub-id pub-id-type="pmid">16395290</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Leira</surname><given-names>EC</given-names></name><name><surname>Ajax</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name><article-title>Limb-shaking carotid transient ischemic attacks successfully treated with modification of the antihypertensive regimen</article-title><source>Arch Neurol</source><year>1997</year><volume>3</volume><fpage>904</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1001/archneur.1997.00550190090019</pub-id><pub-id pub-id-type="pmid">9236580</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Rothwell</surname><given-names>PM</given-names></name><name><surname>Howard</surname><given-names>SC</given-names></name><name><surname>Spence</surname><given-names>JD</given-names></name><article-title>Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease</article-title><source>Stroke</source><year>2003</year><volume>3</volume><fpage>2583</fpage><lpage>2590</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000094424.38761.56</pub-id><pub-id pub-id-type="pmid">14593126</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Banks</surname><given-names>JL</given-names></name><name><surname>Marotta</surname><given-names>CA</given-names></name><article-title>Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis</article-title><source>Stroke</source><year>2007</year><volume>3</volume><fpage>1091</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000258355.23810.c6</pub-id><pub-id pub-id-type="pmid">17272767</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Fox</surname><given-names>AJ</given-names></name><article-title>How to measure carotid stenosis</article-title><source>Radiology</source><year>1993</year><volume>3</volume><fpage>316</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">8421726</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Hofmeijer</surname><given-names>J</given-names></name><name><surname>Anema</surname><given-names>PC</given-names></name><name><surname>van den Tweel</surname><given-names>I</given-names></name><article-title>New algorithm for treatment allocation reduced selection bias and loss of power in small trials</article-title><source>J Clin Epidemiol</source><year>2008</year><volume>3</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.04.002</pub-id><pub-id pub-id-type="pmid">18177784</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Bokkers</surname><given-names>RP</given-names></name><name><surname>Bremmer</surname><given-names>JP</given-names></name><name><surname>van Berckel</surname><given-names>BN</given-names></name><name><surname>Lammertsma</surname><given-names>AA</given-names></name><name><surname>Hendrikse</surname><given-names>J</given-names></name><name><surname>Pluim</surname><given-names>JP</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Boellaard</surname><given-names>R</given-names></name><name><surname>Klijn</surname><given-names>CJ</given-names></name><article-title>Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion</article-title><source>J Cereb Blood Flow Metab</source><year>2010</year><volume>3</volume><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2009.204</pub-id><pub-id pub-id-type="pmid">19809464</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Brix</surname><given-names>G</given-names></name><name><surname>Zaers</surname><given-names>J</given-names></name><name><surname>Adam</surname><given-names>LE</given-names></name><name><surname>Bellemann</surname><given-names>ME</given-names></name><name><surname>Ostertag</surname><given-names>H</given-names></name><name><surname>Trojan</surname><given-names>H</given-names></name><name><surname>Haberkorn</surname><given-names>U</given-names></name><name><surname>Doll</surname><given-names>J</given-names></name><name><surname>Oberdorfer</surname><given-names>F</given-names></name><name><surname>Lorenz</surname><given-names>WJ</given-names></name><article-title>Performance evaluation of a whole-body PET scanner using the NEMA protocol</article-title><source>J Nucl Med</source><year>1997</year><volume>3</volume><fpage>1614</fpage><lpage>1623</lpage><pub-id pub-id-type="pmid">9379202</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Bremmer</surname><given-names>JP</given-names></name><name><surname>van Berckel</surname><given-names>BN</given-names></name><name><surname>Persoon</surname><given-names>S</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Lammertsma</surname><given-names>AA</given-names></name><name><surname>Kloet</surname><given-names>R</given-names></name><name><surname>Luurtsema</surname><given-names>G</given-names></name><name><surname>Rijbroek</surname><given-names>A</given-names></name><name><surname>Klijn</surname><given-names>CJ</given-names></name><name><surname>Boellaard</surname><given-names>R</given-names></name><article-title>Day-to-day test-retest variability of CBF, CMRO(2), and OEF measurements using dynamic (15)O PET Studies</article-title><source>Mol Imaging Biol</source><year>2011</year><volume>3</volume><fpage>759</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1007/s11307-010-0382-1</pub-id><pub-id pub-id-type="pmid">20700768</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Tatu</surname><given-names>L</given-names></name><name><surname>Moulin</surname><given-names>T</given-names></name><name><surname>Bogousslavsky</surname><given-names>J</given-names></name><name><surname>Duvernoy</surname><given-names>H</given-names></name><article-title>Arterial territories of the human brain: cerebral hemispheres</article-title><source>Neurology</source><year>1998</year><volume>3</volume><fpage>1699</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1212/WNL.50.6.1699</pub-id><pub-id pub-id-type="pmid">9633714</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Woods</surname><given-names>RP</given-names></name><name><surname>Grafton</surname><given-names>ST</given-names></name><name><surname>Holmes</surname><given-names>CJ</given-names></name><name><surname>Cherry</surname><given-names>SR</given-names></name><name><surname>Mazziotta</surname><given-names>JC</given-names></name><article-title>Automated image registration: I. General methods and intrasubject, intramodality validation</article-title><source>J Comput Assist Tomogr</source><year>1998</year><volume>3</volume><fpage>139</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1097/00004728-199801000-00027</pub-id><pub-id pub-id-type="pmid">9448779</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Boellaard</surname><given-names>R</given-names></name><name><surname>Knaapen</surname><given-names>P</given-names></name><name><surname>Rijbroek</surname><given-names>A</given-names></name><name><surname>Luurtsema</surname><given-names>GJ</given-names></name><name><surname>Lammertsma</surname><given-names>AA</given-names></name><article-title>Evaluation of basis function and linear least squares methods for generating parametric blood flow images using 15O-water and positron emission tomography</article-title><source>Mol Imaging Biol</source><year>2005</year><volume>3</volume><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1007/s11307-005-0007-2</pub-id><pub-id pub-id-type="pmid">16080023</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Derdeyn</surname><given-names>CP</given-names></name><name><surname>Videen</surname><given-names>TO</given-names></name><name><surname>Fritsch</surname><given-names>SM</given-names></name><name><surname>Carpenter</surname><given-names>DA</given-names></name><name><surname>Grubb</surname><given-names>RL</given-names><suffix>Jr</suffix></name><name><surname>Powers</surname><given-names>WJ</given-names></name><article-title>Compensatory mechanisms for chronic cerebral hypoperfusion in patients with carotid occlusion</article-title><source>Stroke</source><year>1999</year><volume>3</volume><fpage>1019</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1161/01.STR.30.5.1019</pub-id><pub-id pub-id-type="pmid">10229738</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Yamauchi</surname><given-names>H</given-names></name><name><surname>Fukuyama</surname><given-names>H</given-names></name><name><surname>Nagahama</surname><given-names>Y</given-names></name><name><surname>Oyanagi</surname><given-names>C</given-names></name><name><surname>Okazawa</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>M</given-names></name><name><surname>Konishi</surname><given-names>J</given-names></name><name><surname>Shio</surname><given-names>H</given-names></name><article-title>Long-term changes of hemodynamics and metabolism after carotid artery occlusion</article-title><source>Neurology</source><year>2000</year><volume>3</volume><fpage>2095</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1212/WNL.54.11.2095</pub-id><pub-id pub-id-type="pmid">10851369</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Markus</surname><given-names>HS</given-names></name><name><surname>Harrison</surname><given-names>MJ</given-names></name><name><surname>Adiseshiah</surname><given-names>M</given-names></name><article-title>Carotid endarterectomy improves haemodynamics on the contralateral side: implications for operating contralateral to an occluded carotid artery</article-title><source>Br J Surg</source><year>1993</year><volume>3</volume><fpage>170</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1002/bjs.1800800212</pub-id><pub-id pub-id-type="pmid">8443641</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Widder</surname><given-names>B</given-names></name><name><surname>Kleiser</surname><given-names>B</given-names></name><name><surname>Krapf</surname><given-names>H</given-names></name><article-title>Course of cerebrovascular reactivity in patients with carotid artery occlusions</article-title><source>Stroke</source><year>1994</year><volume>3</volume><fpage>1963</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.1161/01.STR.25.10.1963</pub-id><pub-id pub-id-type="pmid">7916501</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Persoon</surname><given-names>S</given-names></name><name><surname>Luitse</surname><given-names>MJ</given-names></name><name><surname>de Borst</surname><given-names>GJ</given-names></name><name><surname>van der Zwan</surname><given-names>A</given-names></name><name><surname>Algra</surname><given-names>A</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Klijn</surname><given-names>CJ</given-names></name><article-title>Symptomatic internal carotid artery occlusion: a long-term follow-up study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2011</year><volume>3</volume><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2010.208330</pub-id><pub-id pub-id-type="pmid">20884678</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Buczek</surname><given-names>J</given-names></name><name><surname>Karlinski</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>A</given-names></name><name><surname>Bialek</surname><given-names>P</given-names></name><name><surname>Czlonkowska</surname><given-names>A</given-names></name><article-title>Hyperperfusion syndrome after carotid endarterectomy and carotid stenting</article-title><source>Cerebrovasc Dis</source><year>2013</year><volume>3</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1159/000350736</pub-id><pub-id pub-id-type="pmid">23817298</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Bergsneider</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>HM</given-names></name><name><surname>Glenn</surname><given-names>TC</given-names></name><name><surname>Vespa</surname><given-names>PM</given-names></name><name><surname>Hovda</surname><given-names>DA</given-names></name><name><surname>Phelps</surname><given-names>ME</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><article-title>Accuracy of a method using short inhalation of (15)O-O(2) for measuring cerebral oxygen extraction fraction with PET in healthy humans</article-title><source>J Nucl Med</source><year>2004</year><volume>3</volume><fpage>765</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">15136624</pub-id></mixed-citation></ref></ref-list></back></article>